锥形束CT肿瘤血容量能否预测结直肠癌肝转移化疗栓塞的疗效?一项观察性研究结果
这项单中心观察性研究纳入34例连续接受伊立替康药物洗脱微球(DEBIRI)化疗栓塞的结直肠癌肝转移患者,用C臂锥形束CT测量肿瘤实质血容量(PBV),发现基线PBV及PBV变化百分比与2个月肿瘤疗效强相关,提示术中PBV可能预测DEBIRI化疗栓塞的疗效。
要点
- 基线PBV及PBV变化百分比与2个月肿瘤疗效强相关(rho分别为-0.8587和0.8027,p均为0.00001)。
- DEBIRI化疗栓塞前肿瘤PBV每增加1 ml/1000 ml,直径缩小0.54 mm(p<0.005)。
- DEBIRI化疗栓塞后PBV每下降1%,肿瘤缩小0.75 mm(p<0.005)。
核心结论
- 术中C臂锥形束CT测量的肿瘤实质血容量(PBV)可能预测结直肠癌肝转移对DEBIRI化疗栓塞的疗效。
研究设计与样本
- 单中心观察性研究,纳入2015年3月至2016年12月间连续转诊接受DEBIRI化疗栓塞的34例结直肠癌肝转移患者,符合赫尔辛基宣言并经机构审查委员会批准,由两名独立阅片者 review 所有数据,以多排CT按RECIST 1.0于基线和DEBIRI化疗栓塞后2个月评估肿瘤大小,并于DEBIRI化疗栓塞前后测量PBV。
诊断标准与关键数值
- 基线PBV与2个月肿瘤疗效的Spearman秩相关系数rho=-0.8587(p=0.00001),PBV变化百分比与2个月肿瘤疗效的rho=0.8027(p=0.00001)。
临床应用与阅片要点
- 作者认为术中PBV可能预测DEBIRI化疗栓塞的肿瘤疗效,原文未据此给出具体阅片或报告建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine whether intraprocedural C-arm cone-beam CT (CBCT) parenchymal blood volume (PBV) can predict the response of colorectal cancer liver metastases (CRCLM) 2 months after irinotecan drug-eluting bead (DEBIRI) chemoembolization.
MATERIALS AND METHODS: This single-center observational study was compliant with the Helsinki Declaration and approved by our institutional review board. Thirty-four consecutive CRCLM patients referred for DEBIRI chemoembolization were enrolled between March 2015 and December 2016. Tumor size was assessed at baseline and 2 months after DEBIRI chemoembolization by multidetector CT (Response Evaluation Criteria in Solid Tumors RECIST 1.0), and PBV was measured before and after DEBIRI chemoembolization. Two independent readers reviewed all data. We determined the potential correlation (Spearman's rank correlation) between intraprocedural PBV values and tumor response at 2 months. The relationship between tumor response and PBV was studied using a mixed model. A logistic regression model was applied to study the relationship between patient "Responder/Non-responder" and PBV.
RESULTS: There was a strong correlation between baseline PBV or the percent change of PBV and the 2-month tumor response (rho = - 0.8587 (p = 0.00001) and rho = 0.8027 (p = 0.00001), respectively). The mixed model showed that an increase of 1 ml/1000 ml in PBV of a tumor before DEBIRI chemoembolization led to a 0.54 mm decrease in diameter (p < 0.005). A 1% decrease in PBV after DEBIRI chemoembolization resulted in tumor shrinkage of 0.75 mm (p < 0.005). The logistic regression model showed that patients with a 1% smaller mean decrease of PBV after DEBIRI chemoembolization had a 10% lower likelihood of achieving disease control (OR = 0.9, 95% confidence interval (CI) = 0.81-1; p = 0.0493).
CONCLUSION: Intraprocedural PBV may predict tumor response to DEBIRI chemoembolization.
KEY POINTS: • There is a strong relationship between the parenchymal blood volume (PBV) of colorectal liver metastases before DEBIRI chemoembolization and tumor response at 2 months. • Higher PBV values before DEBIRI chemoembolization correlate with greater tumor shrinkage, but only if the PBV decreases by more than 70% after DEBIRI chemoembolization. • Each increase of 1% in the mean decrease of PBV after DEBIRI chemoembolization resulted in a 10% lower likelihood of achieving disease control (OR = 0.9, 95% confidence interval (CI) = 0.81-1; p = 0.0493).
引用
- Pellerin O, Pereira H, Moussa N, et al. Can cone-beam CT tumor blood volume predicts the response to chemoembolization of colorectal liver metastases? Results of an observational study. Eur Radiol. 2019. PMID: 30788587. doi:10.1007/s00330-019-6007-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。